<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="19560">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02852252</url>
  </required_header>
  <id_info>
    <org_study_id>822933</org_study_id>
    <nct_id>NCT02852252</nct_id>
  </id_info>
  <brief_title>Solid Tumor Cancer Surgery With or Without Intraoperative Imaging: A Registry</brief_title>
  <official_title>Solid Tumor Cancer Surgery With or Without Intraoperative Imaging: A Registry Optional Sub-Study I: ICG Optional Sub-Study II: OTL38</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Pennsylvania</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Pennsylvania</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study objective is to collect prospective data on cancer patients who undergo surgery
      and intraoperative imaging. The registry will include (but not limited to) cancer type,
      stage, intraoperative challenges to the surgeon, usage and results of intraoperative
      imaging, and recurrence surveillance.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2016</start_date>
  <primary_completion_date type="Anticipated">July 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>10 Years</target_duration>
  <primary_outcome>
    <measure>Tissue to Background Ratio</measure>
    <time_frame>2 years</time_frame>
    <description>Enhance ability to detect malignant tissues in situ and ex vivo.</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Bladder Cancer</condition>
  <condition>Gastric Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>OTL38</intervention_name>
    <description>Patients will be given imaging agent 2-3 hours before surgery to assist in imaging.</description>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ICG</intervention_name>
    <description>Patients will be given imaging agent 24 hours before surgery to assist in imaging.</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with a high clinical suspicion of cancer, scheduled to undergo surgery.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult patients &gt;/= 18 years of age.

          -  Patients presenting with esophagogastric or bladder cancer.

          -  Good operative candidate as determined by the treating physician and/or
             multidisciplinary team.

          -  Subject capable of giving informed consent and participating in the process of
             consent.

        Exclusion Criteria:

          -  Pregnant women as determined by urinary or serum beta hCG within 72 hours of surgery.

          -  Vulnerable patient population.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Sunil Singhal, MD</last_name>
    <phone>215-662-4767</phone>
    <email>sunil.singhal@uphs.upenn.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hospital of the University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sunil Singhal, MD</last_name>
      <phone>215-662-4767</phone>
    </contact>
    <investigator>
      <last_name>Sunil Singhal, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2016</verification_date>
  <lastchanged_date>August 5, 2016</lastchanged_date>
  <firstreceived_date>July 28, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Pennsylvania</investigator_affiliation>
    <investigator_full_name>Sunil Singhall</investigator_full_name>
    <investigator_title>Assistant Professor, University of Pennsylvania School of Medicine</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Stomach Neoplasms</mesh_term>
    <mesh_term>Urinary Bladder Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
